Line of business: BlueAlliance (Commercial) & BlueAlliance Care+ (Medicaid)
The percentage of emergency department (ED) visits members 13 years of age and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose for which there was follow-up.
Two rates are reported:
Any of the following services done with a mental health provider or having a diagnosis of substance use or drug overdose (unintentional) may count as a follow-up visit:
Description | Prescription |
Aldehyde dehydrogenase inhibitor | Disulfiram (oral) |
Antagonist | Naltrexone (oral and injectable) |
Other | Acamprosate (oral; delayed-release tablet) |
Description | Prescription |
Antagonist | Naltrexone (oral) |
Antagonist | Naltrexone (injectable) |
Partial agonist | Buprenorphine (sublingual tablet) |
Partial agonist | Buprenorphine (injection) |
Partial agonist | Buprenorphine (implant) |
Partial agonist | Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film) |
The analysis of any medical coding question related to a measure is dependent on the measure’s technical specifications including the factual situations present related to the member, the practice, the professionals, and the medical services provided.
Should you have specific coding or other questions related to the measure, please send your questions to BlueAlliance@bcbsnd.com.
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).